Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Postponing oncological treatment may be justifiable in patients with low-grade gastric MALT lymphoma, after successful eradication of H. pylori

A watch-and-wait approach to the management of localized low-grade gastric MALT-type lymphoma after the eradication of Helicobacter pylori could be a valid strategy claims a research letter in the journal The Lancet.

News image

fiogf49gjkf04

Helicobacter pylori infection is known to play an important part in the development and progression of MALT (mucosa-associated lymphoid tissue)-type gastric lymphoma, and eradication of H. pylori is well established as an initial treatment for MALT lymphoma that is confined to the gastric wall.

In cases where progression of the disease, or of lymphoma infiltrates, continues 12 months after eradication of H. pylori, patients are usually referred for surgery or radiotherapy.

In a research letter to the latest edition of The Lancet, Professor Wolfgang Fischbach and colleagues from the University of Würzburg, in Würzburg, Germany, describe their experiences with 7 patients who declined further treatment.

The research group investigated 5 male and 2 female patients, aged 43 to 69 years, who were diagnosed with low-grade gastric MALT-type lymphoma (extranodal marginal zone B-cell lymphoma, according to the revised European American lymphoma (REAL) and WHO classifications) by review of centralized histological records.

H pylori infection was shown histologically and by the rapid urease test.

Complete diagnostic work-up, which included abdominal and cervical ultrasound, thoracic and abdominal CT, bone marrow puncture, and endoscopic gastric ultrasound, showed stage I lymphoma (according to the Ann Arbor staging system) in all patients.

Patients received triple therapy with omeprazole, clarithromycin, and metronidazole or amoxycillin, and were followed up with endoscopy and gastric biopsy every 3 months.

Endoscopy showed that the initial macroscopic lesions had returned to normal or revealed features of post H pylori gastritis only.

All patients became negative for H. pylori by the rapid urease test, and on repeat biopsies.

However, lymphoma regression was not achieved within 12 months after successful eradication of the bacterium, as shown by histological and immunohistochemical examination.

Potential strategies for gastric MALT lymphoma - could be broader than previously thought
The Lancet

The researchers took biopsy samples by use of a mapping protocol (antrum, 4 biopsies; corpus, 4; fundus, 2; and any visible lesion, 8 to 10).

Clonality and presence of t(11;18) translocations were then determined by standard immunoglobulin-gene-rearrangement-PCR and PCR for API2-MALT1 chimeric transcripts.

The researchers found there to be no signs of lymphoma progression or high-grade transformation within a median observation time of 34 months (range 20-44 months).

A total of 4 out of 5 patients tested were positive for t(11;18) at initial diagnosis.

One of these patients became negative for t(11;18) 20 months after eradication therapy, whereas the other 3 remained positive during follow-up.

Commenting on their findings, the researchers say that they saw no cases of lymphoma progression or high-grade transformation within an observation period of almost 3 years.

They add that the potential strategies for management of patients with gastric MALT lymphoma might, therefore, be broader than previously thought, and could include a watch-and-wait strategy.

Continuing, they say that the finding that more cases were t(11;18) positive than were negative is in accord with those of recent reports on MALT lymphoma after H. pylori eradication, but that since patients who are negative for t(11;18) show many more clonal aberrations than those who are positive, as shown by microsatellite analysis, such patients may need more intensive follow-up.

The research group end by cautioning that they investigated only a few cases and so this strategy should be tested in a larger series of patients with long-term follow-up, including detailed molecular analyses.

Also, patients managed by a watch-and-wait strategy should be compared with those receiving standard oncological treatment.

"We believe that to postpone oncological treatment is justifiable in patients with minimal residual stage I low-grade gastric MALT lymphoma, after successful eradication of H. pylori. Very thorough investigations are, however, mandatory when deciding to do so."

Lancet 2002; 360(9332): 547-548
19 August 2002

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us